Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Chris Lange | Jan 5, 2015 at 4:25 PM EST

Is a Generic Diovan for You?

What are investors, and patients, supposed to think when is launching a generic version of Diovan?

Chris Lange | Jan 5, 2015 at 4:19 PM EST

Rite Aid Scores New Street-High Analyst Price Target

Pharmacy and drug store player Rite Aid now has a new street-high analyst target price from Credit Suisse.

Chris Lange | Dec 31, 2014 at 8:40 AM EST

New Biotech ETF Hits the Market

The ALPS Medical Breakthroughs ETF debuted on the market Wednesday and is focused on research and development opportunities in biotechnology…

Jon C. Ogg | Dec 30, 2014 at 7:45 AM EST

The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers

Out of 28 biotech stocks with market capitalization rates north of $300 million that were up 100% or more in…

Chris Lange | Dec 29, 2014 at 1:55 PM EST

Flex Pharma Files for IPO

Flex Pharma Inc. has filed with the Securities and Exchange Commission (SEC) for its initial public offering.

Chris Lange | Dec 29, 2014 at 10:45 AM EST

Is Gilead Already Coming Back Into Favor?

Is it possible that Gilead Sciences is already coming back into favor after just a week of being in the…

Lee Jackson | Dec 29, 2014 at 10:05 AM EST

5 Top Pharmaceutical Stock Picks for 2015

In a new research report, the SunTrust Robinson Humphrey team highlights the top pharmaceutical stocks to buy for 2015.

Chris Lange | Dec 23, 2014 at 12:15 PM EST

Analysts Predict Big Value Trap for Gilead Investors

Analysts are beginning to make their calls for what the future will hold for Gilead Sciences, AbbVie and Express Scripts.

Lee Jackson | Dec 23, 2014 at 9:50 AM EST

RBC’s 5 Top Biotech Stocks to Buy for 2015

One sector that could be poised to do well could be the biotech arena, and the team at RBC has…

Chris Lange | Dec 22, 2014 at 1:20 PM EST

What the AbbVie and Express Script Deal Means for Gilead

AbbVie and Express Scripts have entered into an exclusive agreement under which Express Scripts will distribute AbbVie's hepatitis treatment.

Chris Lange | Dec 19, 2014 at 2:58 PM EST

Merrill Lynch’s Top Health Care Stock Picks for 2015

24/7 Wall St. has compiled a list health care stocks that Merrill Lynch expects to be top performers in 2015.

Chris Lange | Dec 19, 2014 at 11:15 AM EST

Juno, the Last IPO of 2014, Enters the Market With a Bang

Juno Therapeutics debuted on the market Friday morning and has made a big splash.

Douglas A. McIntyre | Dec 19, 2014 at 6:34 AM EST

Nurses Are the Most Trusted People in America

Nurses are the most trusted workers in America, based on honesty and ethical standards. Doctors come in second.

Jon C. Ogg | Dec 17, 2014 at 1:05 PM EST

Is a Biosimilar (Generic) Top Cancer Drug for You?

A biosimilar application filing from Apotex has been accepted by the Food and Drug Administration for version of Amgen's Neulasta.

Chris Lange | Dec 17, 2014 at 9:55 AM EST

Are Volcano Shareholders Getting Enough in the Buyout?

Guided therapy tools maker Volcano has announced that it has entered into a definitive agreement to be acquired by Koninklijke…

1 … 273 274 275 276 277 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Is a Generic Diovan for You?

Rite Aid Scores New Street-High Analyst Price Target

New Biotech ETF Hits the Market

The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers

Flex Pharma Files for IPO

Is Gilead Already Coming Back Into Favor?

5 Top Pharmaceutical Stock Picks for 2015

Analysts Predict Big Value Trap for Gilead Investors

RBC’s 5 Top Biotech Stocks to Buy for 2015

What the AbbVie and Express Script Deal Means for Gilead

Merrill Lynch’s Top Health Care Stock Picks for 2015

Juno, the Last IPO of 2014, Enters the Market With a Bang

Nurses Are the Most Trusted People in America

Is a Biosimilar (Generic) Top Cancer Drug for You?

Are Volcano Shareholders Getting Enough in the Buyout?

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

‘Your Knowledge of Money and How It Works Is Nil’: Suze Orman to 62-Year-Old Who Nearly Locked His Wife Into $605 a Month

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

Parasite Outbreak Fears Crush Restaurant Sales Weeks After RFK Jr. Said It Was “Under Control”

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

Health and Healthcare Articles

All Health and Healthcare Articles

Is a Generic Diovan for You?

Rite Aid Scores New Street-High Analyst Price Target

New Biotech ETF Hits the Market

The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers

Flex Pharma Files for IPO

Is Gilead Already Coming Back Into Favor?

5 Top Pharmaceutical Stock Picks for 2015

Analysts Predict Big Value Trap for Gilead Investors

RBC’s 5 Top Biotech Stocks to Buy for 2015

What the AbbVie and Express Script Deal Means for Gilead

Merrill Lynch’s Top Health Care Stock Picks for 2015

Juno, the Last IPO of 2014, Enters the Market With a Bang

Nurses Are the Most Trusted People in America

Is a Biosimilar (Generic) Top Cancer Drug for You?

Are Volcano Shareholders Getting Enough in the Buyout?

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

‘Your Knowledge of Money and How It Works Is Nil’: Suze Orman to 62-Year-Old Who Nearly Locked His Wife Into $605 a Month

Featured Reads

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.